EICHORCondition: Mild Cognitive Impairment Due to Alzheimer's Disease · Alzheimer's Disease Dementia · Sponsor: Biogen
In this study, researchers will learn more about a study drug called diranersen (BIIB080). The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if diranersen can slow the worsening of AD more than placebo. It will focus on what dose of diranersen slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. * Clinicians use the CDR-SB to measure several categories of dementia symptoms. * The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of diranersen. The study will be split into 2 parts. The 1st part is the Placebo-Controlled Period. The 2nd part is the Long-Term Extension (LTE) Period. The 2nd part of the study will help researchers learn about the long-term safety of diranersen, and how it affects the participant's daily life, thinking, and memory abilities in the longer term. A description of how the study will be done is given below. * After screening, participants will first receive either a low dose or high dose of diranersen, or a placebo, as an injection into the fluid around the spinal cord (cerebrospinal fluid). A placebo looks like the study drug but contains no real medicine. * Participants will receive diranersen or placebo once every 12 weeks or 24 weeks. * After 76 weeks of trea…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Xenoscience Inc. | Phoenix, Arizona, United States | — |
| HonorHealth Neurology | Scottsdale, Arizona, United States | — |
| Banner Sun Health Research Institute | Sun City, Arizona, United States | — |
| Center for Neurosciences | Tucson, Arizona, United States | — |
| Mary S. Easton Center for Alzheimer's Disease Research, UCLA | Los Angeles, California, United States | — |
| PNS Clinical Research, LLC dba | Orange, California, United States | — |
| Stanford Hospital and Clinics | Palo Alto, California, United States | — |
| Sutter Institute for Medical Research | Sacramento, California, United States | — |
| University of California San Diego Medical Center | San Diego, California, United States | — |
| University of California San Francisco (PARENT) | San Francisco, California, United States | — |
| Rocky Mountain Movement Disorders Center, PC | Englewood, Colorado, United States | — |
| Charter Research, LLC | Lady Lake, Florida, United States | — |
+ 126 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05399888